Trial Profile
A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 275
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 17 Mar 2022 Status changed from active, no longer recruiting to completed.
- 28 Jan 2022 This trial has been completed in Germany (Date of the global end of the trial : 12-Nov-2021), according to European Clinical Trials Database record.
- 04 Dec 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.